Another complement factor enters the deal-making frame
Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
Argenx sets a high bar with a novel drug class
A new mechanism for certain autoimmune conditions takes a big step forward with impressive pivotal data on Argenx’s efgartigimod.
Pegasus flies for Apellis, up to a point
The study marks victory against Soliris, but Apellis could still find the market hard to crack.
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
After a delay Wave will finally see data for its Huntington's disease projects while Argenx's subcutaneous efgartigimod needs to keep the competition at bay.
Alexion pays Achillion a $930m complement
A week after UCB bought Ra to get hold of its complement inhibitor, Alexion takes out Achillion for much the same reason.
